Effects of haloperidol and GM1 ganglioside treatment on striatal D2 receptor binding and dopamine turnover

Life Sciences

Volumn 62, Issue 13, 1998, Pages 1161-1169

  Vital, M A B F ^a   Florio J C ^c   Frussa Filho, R ^c   De Lucia, R ^c   Tufik, S ^c   Palermo Neto, João ^b  

^a FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c NONE

Author keywords

D2 receptor binding; DOPAC; Dopamine; Dopaminergic supersensitivity; GM1 ganglioside; Haloperidol; HVA

Indexed keywords

3,4 DIHYDROXYPHENYLACETIC ACID; CATECHOLAMINE; DOPAMINE; DOPAMINE 2 RECEPTOR; GANGLIOSIDE GM1; HALOPERIDOL; HOMOVANILLIC ACID; MONOSIALOGANGLIOSIDE; SPIPERONE; DOPAMINE RECEPTOR BLOCKING AGENT; TRITIUM;

ANIMAL EXPERIMENT; ARTICLE; BEHAVIOR; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE METABOLISM; DOSE RESPONSE; DRUG MIXTURE; DRUG WITHDRAWAL; HORMONE RECEPTOR INTERACTION; INTRAPERITONEAL DRUG ADMINISTRATION; NONHUMAN; PSYCHOSIS; RAT; RECEPTOR AFFINITY; RECEPTOR DENSITY; SYNAPSE; TARDIVE DYSKINESIA; ANIMAL; DRUG ADMINISTRATION; DRUG EFFECT; DRUG POTENTIATION; KINETICS; MALE; METABOLISM; ULTRASTRUCTURE; WISTAR RAT;

ANIMALS; CORPUS STRIATUM; DOPAMINE; DOPAMINE ANTAGONISTS; DRUG ADMINISTRATION SCHEDULE; DRUG SYNERGISM; G(M1) GANGLIOSIDE; HALOPERIDOL; KINETICS; MALE; RATS; RATS, WISTAR; RECEPTORS, DOPAMINE D2; SPIPERONE; TRITIUM;

EID: 0032548496     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0024-3205(98)00042-3     Document Type: Article

References (47)

1. 1. J. KANE, G. HONIGFELD, J. SINGER, H. MELTZER and Clozaril Collaborative Study Group, Arch. Gen. Psychiat. 45 789-796 (1988).
2. 2. T. KAKIGI, X.M. GAO and C.A. TAMMINGA, J. Neural. Transm. [Gen. Sect.] 101 41-49 (1994).
3. 3. H.L. KLAWANS, Am. J. Psychiat. 130 82-86 (1973).
4. 4. D. TARSY and R.J. BALDESSARINI, Neuropharmacol. 13 927-940 (1974).
5. 5. A. CLOW, P. JENNER and C.D. MARSDEN, Europ. J. Pharmacol. 57 365-375 (1979).
6. 6. M.M. BERNARDI, H. DE SOUZA and J. PALERMO-NETO, Psychopharmacol. 73 171-175 (1981).
7. 7. N.M.J. RUPNIAK, G. KILPATRICK, M.D. HALL, P. JENNER and C.D. MARSDEN, Psychopharmacol. 84 512-519 (1984).
8. 8. D.E. CASEY, Psychopharmacology: The Fourth Generation Of Progress, F.E. Bloom and D.J. Kupfer (Eds.), 1497-1502, Raven Press, New York, (1995).
9. 9. L.F. AGNATI, K. FUXE, F. BENFENATI, N. BATTISTINI, I. ZINI and G. TOFFANO, Neuros. Lett. 40 293-297 (1983).
10. 10. J.S. SCHNEIDER, A. POPE, K. SIMPSON, J. TAGGART, M.G. SMITH and L. DISTEFANO, Science 256 843-845 (1992).
11. 11. M. HADJICONSTANTINOU, Z.L. ROSSETI, C.R. PAXTON and N.H. NEFF, Neuropharmacol. 25 1075-1077 (1986).
12. 12. J.S. SCHNEIDER, D.P. ROELTGEN, D.S. ROTHBLAT, J. CHAPAS-CRILLY, L. SERAYDARIAN and J. RAO, Neurology 45 1149-1154 (1995).
13. 13. O.A. ANDREASSEN and H.A. JORGENSEN, Psychopharmacol. 116 517-522 (1994).
14. 14. T.I. LIDSKY, J.S. SCHNEIDER, L.G. ZUCK, E. YABOLONSKY-ALTER and S.P. BANERJEE, Neurodegen. 3 135-140 (1994).
15. 15. U. SCHRÖDER, H. SCHRÖDER, W. AUGUSTIN and B.A. SABEL, J. Pharmacol. Experim. Therap. 271 1193-1196 (1994).
16. 16. M.A.B.F. VITAL, R. FRUSSA-FILHO and J. PALERMO-NETO, Life Sci. 56 2299-2307 (1995).
17. 17. J. GLOWINSKI and L.L. IVERSEN, J. Neurochem. 13 655-659 (1966).
18. 18. M.G.N. MAZZACORATI, D. AMADO and E.A. CAVALHEIRO, Braz. J. Med. Biol. Res. 23 255-262 (1990).
19. 19. L.F. FELICIO, J.C. FLÓRIO, L.H. SIDER, P.E. CRUZ-CASALLAS and R.S. BRIDGES, Brain Res. Bull. 40 253-256 (1996).
20. 20. D.R. BURT, I. CREESE and S.H. SNYDER, Molecular Pharmacol. 12 800-812 (1976).
21. 21. J.E. LEYSEN, V. GOMMEREN and P.M. LAUDRON, Biochem. Pharmacol. 27 307-316 (1978).
22. 22. R. DE LUCIA, C. SCAVONE and M.A. CAMILLO, Braz. J. Med. Biol. Res. 22 741-743 (1989).
23. 23. T.I. LIDSKY and S.P. BANERJEE, J. Pharmacol. and Experim. Therap. 265 1193-1198 (1993).
24. 24. R.J. BALDESSARINI, Goodman & Gilman's The Pharmacological Basis Of Therapeutics, J.G. Hardman, A.G. Gilman and L.E. Limbird (Eds.), 399-430, McGraw-Hill, New York (1996).
25. 25. J. DUNN and N.R. KRAMARCY, Handbook of pharmacology, S.D. Iversen and S.H. Snyder (Eds.), 455-515, Plenum Press, New York (1984).
26. 26. P. SEEMAN, Pharmacol. Rev. 32 229-313 (1980).
27. 27. W.H. CHANG, S.S. JAW and L. TSAY, Europ. J. Pharmacol. 162 151-156 (1989).
28. 28. M.M. BERNARDI and J. PALERMO-NETO, Psychopharmacol. 65 247-250 (1979).
29. 29. R. FRUSSA-FILHO and J. PALERMO-NETO, Braz. J. Med. Biol. Res. 23 463-472 (1990).
30. 30. R. FRUSSA-FILHO and J. PALERMO-NETO, Physiol. Behav. 50 825-830 (1991).
31. 31. R. FRUSSA-FILHO and J. PALERMO-NETO, European J. Pharmacol. 149 323-329 (1988).
32. 32. L.F. FELICIO, J. PALERMO-NETO and A.G. NASELLO, Physiol. Behav. 45 1081-1085 (1989).
33. 33. J. PALERMO-NETO, M.M. BERNARDI and R. SABAN, Pharmacol. 28 203-210 (1984).
34. 34. D.R. BURT, I. CREESE and S.H. SNYDER, Science 196 326-327 (1977).
35. 35. J. PALERMO-NETO, Psychopharmacol. Bull. 18 11-12 (1982).
36. 36. S.Z. LANGER and U. TRENDELENBURG, J. Pharmacol. Exp. Therap. 163 290-299 (1968).
37. 37. C.R. PARTINGTON and J.W. DALY, Molecular Pharmacol. 15 484-491 (1979).
38. 38. J.R. GOLDERING, L.C. OTIS, R.K. YU and R.J. DELORENZO, J. Neurochem. 44 1229-1234 (1985).
39. 39. A. LEON, L. FACCI, D. BENVEGNU and G. TOFFANO, J. Neurochem. 37 350-357 (1981).
40. 40. S.N. PRADHAN and S. BOSE, Psychopharmacology: A generation of progress, M.A. Lipton, A. Di Mascio and K.F. Kellan (Eds.), 271-283 Raven Press, New York (1978).
41. 41. J. DE KEYSER, Clin. Neuropharmacol. 14 562-565 (1991).
42. 42. B.K. YAMAMOTO and S. DAVY, J. Neurochem. 58 1736-1742 (1992).
43. 43. H. MANEV, M. FAVARON, S.E. VICINI, A. GUIDOTTI and E. COSTA, Pharmacol. Experim. Therap. 252 419-427 (1990).
44. 44. S.D. SKAPER and A. LEON, J. Neurotrauma 9 8506-8516 (1992).
45. 45. H. HIGASHI, A. OMORI and T. YAMAGATA, J. Biol. Chem. 267 9831-9838 (1992).
46. 46. M. FAVARON, H. MANEV, H. ALHO, M. BERTOLINO, B. FERRET, A. GUIDOTTI and E. COSTA, Proc. Natl. Acad. Sci. USA 85 7351-7355 (1988).
47. 47. D.A. HALL and P.G. STRANGE, British J. Pharmacol. 121 731-736 (1997).